Pacgen Life Science logo

PBS - Pacgen Life Science Share Price

C$0.03 0.0  0.0%

Last Trade - 16/09/20

Micro Cap
Market Cap £n/a
Enterprise Value £n/a
Revenue £172k
Position in Universe th / 2682
Unlock PBS Revenue
Relative Strength (%)
1m -0.46%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Mar 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.060 0.066 0.066 0.61 0.46 0.35 +42.8%
Balance Sheet
FINANCIAL BRIEF: : For the three months ended 30 June 2020, Pacgen LifeScience Corp revenues decreased 45% to C$62K. Net lossincreased 17% to C$99K. Revenues reflect Product salesdecrease of 82% to C$17K. Higher net loss reflects Generaland administrative increase of 24% to C$69K (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


PBS Revenue Unlock PBS Revenue

Net Income

PBS Net Income Unlock PBS Revenue

Normalised EPS

PBS Normalised EPS Unlock PBS Revenue

PE Ratio Range

PBS PE Ratio Range Unlock PBS Revenue

Dividend Yield Range

PBS Dividend Yield Range Unlock PBS Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
PBS EPS Forecasts Unlock PBS Revenue
Profile Summary

Pacgen Life Science Corporation, formerly Pacgen Biopharmaceuticals Corporation, is a life sciences company focused on the commercialization of life sciences products and services. The Company has a worldwide license to develop and commercialize an antifungal called P113 (also called PAC-113). It has sublicensed its PAC-113 right to General Biologicals Corporation (GBC), which offers non-prescription over-the-counter (OTC) products containing PAC-113 in Taiwan. P113 is a 12 amino-acid antimicrobial peptide derived from a histatin protein found in saliva. Its P113 is used for the treatment of various oral conditions, as well as vaginal, dermatological and ophthalmic conditions. GBC offers products, such as cosmetic skin-care products, oral hygiene products and intimate hygiene products. The oral healthcare product includes Mr.&Mrs.O. It has conducted a Phase IIb dose-ranging clinical trial for PAC-113. Its oral health and woman health products are in the commercialization stage.

Last Annual March 31st, 2020
Last Interim June 30th, 2020
Incorporated April 23, 2004
Public Since April 23, 2004
No. of Shareholders: n/a
No. of Employees: 10
Sector Healthcare
Industry Pharmaceuticals
Exchange TSX Venture Exchange
Shares in Issue 64,815,969
Free Float (0.0%)
Eligible for
PBS Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for PBS
Upcoming Events for PBS
Frequently Asked Questions for Pacgen Life Science
What is the Pacgen Life Science share price?

As of 16/09/20, shares in Pacgen Life Science are trading at C$0.03, giving the company a market capitalisation of £n/a. This share price information is delayed by 15 minutes.

How has the Pacgen Life Science share price performed this year?

Shares in Pacgen Life Science are currently trading at C$0.03 and the price has moved by 100% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Pacgen Life Science price has moved by 78.48% over the past year.

What are the analyst and broker recommendations for Pacgen Life Science?

There are no analysts currently covering Pacgen Life Science.

When will Pacgen Life Science next release its financial results?

Pacgen Life Science is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the Pacgen Life Science dividend yield?

Pacgen Life Science does not currently pay a dividend.

Does Pacgen Life Science pay a dividend?

Pacgen Life Science does not currently pay a dividend.

When does Pacgen Life Science next pay dividends?

Pacgen Life Science does not currently pay a dividend.

How do I buy Pacgen Life Science shares?

To buy shares in Pacgen Life Science you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Pacgen Life Science?

Shares in Pacgen Life Science are currently trading at C$0.03, giving the company a market capitalisation of £n/a.

Where are Pacgen Life Science shares listed? Where are Pacgen Life Science shares listed?

Here are the trading details for Pacgen Life Science:

Country of listing: Canada
Exchange: CVE
Ticker Symbol: PBS
What kind of share is Pacgen Life Science?

We were not able to load our ranking data for Pacgen Life Science

Is there a Pacgen Life Science share price forecast 2021?

We were not able to load any forecast data for Pacgen Life Science.

How can I tell whether the Pacgen Life Science share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Pacgen Life Science. Over the past six months, the relative strength of its shares against the market has been 77.64%. At the current price of C$0.03, shares in Pacgen Life Science are trading at % against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Pacgen Life Science PE Ratio?

We were not able to find PE ratio data for Pacgen Life Science.

Who are the key directors of Pacgen Life Science?

We were unable to find the directors for Pacgen Life Science.

Who are the major shareholders of Pacgen Life Science?

Here are the top five shareholders of Pacgen Life Science based on the size of their shareholding:

General Biologicals Corporation Corporation
Percentage owned: 14.84% (9.62m shares)
Yip, Christina Individual Investor
Percentage owned: 11.05% (7.16m shares)
Wang (Chung Yu) Individual Investor
Percentage owned: 8.96% (5.81m shares)
Savage (Alan Clyde Hayes) Individual Investor
Percentage owned: 8.58% (5.56m shares)
Arya (Rakesh Kumar) Individual Investor
Percentage owned: 7.71% (5.00m shares)
Similar to PBS
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.